Safety and Clinical Response to Combined Immunotherapy with Autologous iNKT Cells and PD-1 + CD8 + T Cells in Patients Failing First-line Chemotherapy in Stage IV Pancreatic Cancer.
Jing WangXiaobo ChengYanling JinBili XiaRan QinWei ZhangHuiliang HuXiaoting MaoLiting ZhouJia YanXiaoyan ZhangJianqing XuPublished in: Cancer research communications (2023)
T cells in 9 patients with advanced pancreatic cancer and failing the first-line chemotherapy. The combined immunotherapy was shown to be feasible in the enrolled patients with limited side effects and optimistic clinical responses, which could bring opportunity of therapeutic advancement.
Keyphrases
- end stage renal disease
- induced apoptosis
- ejection fraction
- newly diagnosed
- chronic kidney disease
- locally advanced
- prognostic factors
- bone marrow
- peritoneal dialysis
- squamous cell carcinoma
- stem cells
- cell therapy
- patient reported outcomes
- cell proliferation
- radiation therapy
- chemotherapy induced
- platelet rich plasma